Literature DB >> 2443243

Biochemistry of azacitidine: a review.

A B Glover1, B Leyland-Jones.   

Abstract

Azacitidine is a pyrimidine ring analog of cytidine that is incorporated into RNA causing alteration in RNA synthesis and processing and resulting in inhibition of protein synthesis. Azacitidine as the deoxynucleotide is also incorporated into DNA inhibiting its synthesis and blocking cytosine methylation by noncompetitive inhibition of DNA methyltransferase. The resulting hypomethylation of DNA is thought to induce gene activation and expression and cell differentiation. This may be an underlying factor in azacitidine's antileukemic activity and also contributes to its carcinogenic and tumor-promoting properties in experimental models.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443243

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  25 in total

Review 1.  Azacitidine: in myelodysplastic syndromes.

Authors:  M Asif A Siddiqui; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

3.  Effect of 5-azacytidine on gene expression in marrow stromal cells.

Authors:  D F Andrews; J Nemunaitis; C Tompkins; J W Singer
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

4.  Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

Authors:  V I Avramis; R A Mecum; J Nyce; D A Steele; J S Holcenberg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.

Authors:  M Monika Belickova; Michaela Dostalova Merkerova; Hana Votavova; Jan Valka; Jitka Vesela; Barbora Pejsova; Hana Hajkova; Jiri Klema; Jaroslav Cermak; Anna Jonasova
Journal:  Int J Hematol       Date:  2016-07-14       Impact factor: 2.490

6.  Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines.

Authors:  Aaron N Nguyen; Paul W Hollenbach; Normand Richard; Antonio Luna-Moran; Helen Brady; Carla Heise; Kyle J MacBeth
Journal:  Lung Cancer (Auckl)       Date:  2010-09-09

7.  Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.

Authors:  J Quddus; K J Johnson; J Gavalchin; E P Amento; C E Chrisp; R L Yung; B C Richardson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 8.  Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Giuseppe Leone; Francesco D'Alò; Giuseppe Zardo; Maria Teresa Voso; Clara Nervi
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

Authors:  Paul W Hollenbach; Aaron N Nguyen; Helen Brady; Michelle Williams; Yuhong Ning; Normand Richard; Leslie Krushel; Sharon L Aukerman; Carla Heise; Kyle J MacBeth
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.